<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="19603"><DrugName>reparixin</DrugName><DrugNamesKey><Name id="42788400">Repertaxin</Name><Name id="42859545">reparixin</Name></DrugNamesKey><DrugSynonyms><Name><Value>Repertaxin</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>DF-1681Y</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>reparixin</Value><Types><Type>USAN</Type></Types></Name><Name><Value>DF-1681</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>266359-83-5</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="26028">Dompe Group</CompanyOriginator><CompaniesPrimary><Company id="26028">Dompe Group</Company><Company id="1071572">SatRx Llc</Company></CompaniesPrimary><CrossReferences><SourceEntity id="19603" type="Drug"><TargetEntity id="289580" type="siDrug">Reparixin</TargetEntity></SourceEntity><SourceEntity id="1071572" type="Company"><TargetEntity id="5037642204" type="organizationId">SatRx OOO</TargetEntity></SourceEntity><SourceEntity id="26028" type="Company"><TargetEntity id="5036373028" type="organizationId">Dompe Group</TargetEntity></SourceEntity><SourceEntity id="1024" type="ciIndication"><TargetEntity id="10063837" type="MEDDRA"></TargetEntity><TargetEntity id="D015427" type="MeSH"></TargetEntity><TargetEntity id="-775574420" type="omicsDisease"></TargetEntity><TargetEntity id="1176" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2988" type="ciIndication"><TargetEntity id="T86.41" type="ICD10"></TargetEntity><TargetEntity id="10024715" type="MEDDRA"></TargetEntity><TargetEntity id="1137" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2989" type="ciIndication"><TargetEntity id="T86.11" type="ICD10"></TargetEntity><TargetEntity id="10023439" type="MEDDRA"></TargetEntity><TargetEntity id="1136" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3141" type="ciIndication"><TargetEntity id="T86.810" type="ICD10"></TargetEntity><TargetEntity id="10051604" type="MEDDRA"></TargetEntity><TargetEntity id="1225" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3657" type="ciIndication"><TargetEntity id="10055113" type="MEDDRA"></TargetEntity><TargetEntity id="589" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="49" type="ciIndication"><TargetEntity id="C50" type="ICD10"></TargetEntity><TargetEntity id="10006279" type="MEDDRA"></TargetEntity><TargetEntity id="D001943" type="MeSH"></TargetEntity><TargetEntity id="-436099203" type="omicsDisease"></TargetEntity><TargetEntity id="588" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="515" type="ciIndication"><TargetEntity id="10044439" type="MEDDRA"></TargetEntity><TargetEntity id="D006084" type="MeSH"></TargetEntity><TargetEntity id="1133" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3131" type="Action"><TargetEntity id="1186" type="Mechanism">Chemokine CXCR2  (IL-8 beta Receptor) Antagonists</TargetEntity><TargetEntity id="3717" type="Mechanism">Chemokine CXCR2  (IL-8 beta Receptor) Inverse Agonists</TargetEntity><TargetEntity id="6004" type="Mechanism">Anti-CXCR2</TargetEntity></SourceEntity><SourceEntity id="1580" type="Action"><TargetEntity id="662" type="Mechanism">IL-8 Inhibitors</TargetEntity><TargetEntity id="1560" type="Mechanism">Anti-Interleukin-8 (IL-8; CXCL8)</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity><SourceEntity id="3128" type="Action"><TargetEntity id="1185" type="Mechanism">Chemokine CXCR1 (IL-8 alpha Receptor) Antagonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-00516" type="ciTarget"><TargetEntity id="178290560335773" type="siTarget">C-X-C chemokine receptor type 1</TargetEntity><TargetEntity id="416" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-00517" type="ciTarget"><TargetEntity id="3158340735793" type="siTarget">C-X-C chemokine receptor type 2</TargetEntity><TargetEntity id="-1840770424" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-00989" type="ciTarget"><TargetEntity id="57981" type="siTarget">C-X-C Chemokine Receptor CXCR1/CXCR2 (IL-8 Receptor) (nonspecified subtype)</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C3">Phase 3 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="2988">Liver transplant rejection</Indication><Indication id="3481">Islet cell transplant rejection</Indication><Indication id="3657">Metastatic breast cancer</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1024">Reperfusion injury</Indication><Indication id="2989">Kidney transplant rejection</Indication><Indication id="3141">Lung transplant rejection</Indication><Indication id="49">Breast tumor</Indication><Indication id="515">Transplant rejection</Indication><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsPrimary><Action id="3131">CXCR2 chemokine antagonist</Action><Action id="1580">IL-8 receptor antagonist</Action><Action id="3128">CXCR1 chemokine antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action><Action id="5580">Chemotaxis inhibitor</Action><Action id="5641">Neutrophil migration inhibitor</Action><Action id="2660">Vasoprotectant</Action><Action id="1545">Anticancer</Action></ActionsSecondary><Technologies><Technology id="648">Intravenous formulation</Technology><Technology id="740">Infusion</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2018-07-17T15:57:57.000Z</LastModificationDate><ChangeDateLast>2018-07-18T00:00:00.000Z</ChangeDateLast><AddedDate>1998-09-09T12:46:05.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="26028" linkType="Company"&gt;Dompe&lt;/ulink&gt; is developing   reparixin (DF-1681; Repertaxin; structure shown), an ibuprofen analog interleukin-8 (IL-8) antagonist that functions by binding to the CXCR-1 and -2 receptors to prevent neutrophil chemotaxis, for the potential prevention of graft tissue damage  in organ transplantation and cancer, including breast cancer [&lt;ulink linkID="297636" linkType="reference"&gt;297636&lt;/ulink&gt;], [&lt;ulink linkID="381532" linkType="reference"&gt;381532&lt;/ulink&gt;], [&lt;ulink linkID="651130" linkType="Reference"&gt;651130&lt;/ulink&gt;]. Russian licensee &lt;ulink linkID="1071572" linkType="Company"&gt;SatRx&lt;/ulink&gt; is also developing the drug for liver transplantation rejection [&lt;ulink linkID="1444232" linkType="Reference"&gt;1444232&lt;/ulink&gt;].   In February 2011, a phase Ib study  was initiated in patients in HER2-negative breast cancer in the US [&lt;ulink linkID="1266093" linkType="Reference"&gt;1266093&lt;/ulink&gt;]; by March 2011, the drug was in phase II for cancer [&lt;ulink linkID="1266091" linkType="Reference"&gt;1266091&lt;/ulink&gt;]. In October 2012, a phase III trial was initiated in the US and Europe in pancreatic islet transplantation [&lt;ulink linkID="1334127" linkType="Reference"&gt;1334127&lt;/ulink&gt;];    in July 2018, the drug was listed as being in phase III development for this indication [&lt;ulink linkID="2054408" linkType="Reference"&gt;2054408&lt;/ulink&gt;]. In January 2015, a pilot phase II trial was ongoing in   orthotopic liver allotransplantation patients [&lt;ulink linkID="1623813" linkType="Reference"&gt;1623813&lt;/ulink&gt;]. In November 2013,  Dompe was seeking to outlicense the drug [&lt;ulink linkID="1501108" linkType="Reference"&gt;1501108&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Dompe is also investigating other  &lt;ulink linkID="54514" linkType="Drug"&gt;IL-8 antagonists&lt;/ulink&gt;.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In September 2012, the FDA granted reparixin Orphan designation for the prevention of graft loss in pancreatic islet transplantation [&lt;ulink linkID="1326926" linkType="Reference"&gt;1326926&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2003, reparixin received Orphan Drug designation from the US FDA for the prevention of delayed graft function after (solid) organ transplantations [&lt;ulink linkID="1623813" linkType="Reference"&gt;1623813&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In July 2011, the EMA's COMP adopted a positive opinion recommending reparixin for Orphan Drug designation, for the prevention of graft rejection in pancreatic islet transplantation [&lt;ulink linkID="1208834" linkType="Reference"&gt;1208834&lt;/ulink&gt;]. In September 2011, the EC granted the drug Orphan status  [&lt;ulink linkID="1230604" linkType="Reference"&gt;1230604&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In September 2001, reparixin received Orphan Drug designation from the EMEA for the prevention of delayed graft function after (solid)  organ transplant [&lt;ulink linkID="1134100" linkType="Reference"&gt;1134100&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Commonwealth of Independent States&lt;/subtitle&gt;In June 2013 launch in Russia was planned  for 2016 [&lt;ulink linkID="1444232" linkType="Reference"&gt;1444232&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Transplant rejection&lt;/subtitle&gt;In March 2015, a multicenter, open-label, randomized, pilot, phase II trial (&lt;ulink linkID="286203" linkType="Protocol"&gt;NCT03031470&lt;/ulink&gt;; TPL-RPX-01) to evaluate the efficacy and safety of reparixin for the prevention of early allograft dysfunction was initiated in patients (expected n = 100) who were undergoing orthotopic liver transplantation in the Belarus and Russia. In January 2017, the trial was expected to complete in June 2017 [&lt;ulink linkID="1896110" linkType="Reference"&gt;1896110&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2013, Dompe announced the launch of a randomized, double-blind, multicenter, placebo-controlled, phase II/III trial (REP0112) in the US, in patients with autologous islet cell transplantation (expected n = 100), at the 14th world congress of the international pancreas and islet transplant association (IPITA 2013) in Monterey, California, US. At that time, first patient was expected to be enrolled by the end of 2013 and results were expected in early 2016 [&lt;ulink linkID="1481241" linkType="Reference"&gt;1481241&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2013, open-label, phase II/III trials to evaluate the safety and efficacy of reparixin in the prevention of early allograft dysfunction in liver transplants were planned to start in September 2013  [&lt;ulink linkID="1444232" linkType="Reference"&gt;1444232&lt;/ulink&gt;]. In January 2015, a pilot phase II trial was ongoing for the prevention of early allograft dysfunction in patients after orthotopic liver allotransplantation (OLAT) [&lt;ulink linkID="1623813" linkType="Reference"&gt;1623813&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2012, a randomized, double-blind, parallel assigned, international, multicenter phase III trial , REP0211 (&lt;ulink linkID="117689" linkType="Protocol"&gt;NCT01817959&lt;/ulink&gt;: REP0211) trial was initiated in patients with type 1 diabetes (expected n = 42) undergoing pancreatic islet transplantation, in the US and Europe. At that time, first patient was enrolled [&lt;ulink linkID="1334127" linkType="Reference"&gt;1334127&lt;/ulink&gt;], [&lt;ulink linkID="1916209" linkType="Reference"&gt;1916209&lt;/ulink&gt;]. In July 2013, the trial was expected to enroll  50 patients   [&lt;ulink linkID="1451111" linkType="Reference"&gt;1451111&lt;/ulink&gt;]. In October 2016, the trial was completed [&lt;ulink linkID="1916209" linkType="Reference"&gt;1916209&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2010, Dompe began a  phase II open-label study (&lt;ulink linkID="71334" linkType="Protocol"&gt;NCT01220856&lt;/ulink&gt;, REP0110, 2010-019424-31) in patients in  type 1 diabetes patients (n =  10) undergoing pancreatic islet transplantation in Italy and Germany. Patients were to  be randomized to receive either reparixin or no intervention. The study was expected to be completed in   October 2012 [&lt;ulink linkID="1140863" linkType="Reference"&gt;1140863&lt;/ulink&gt;]. In October 2011, interim phase II clinical data were to be presented at the CTS-IXA Congress in Miami, FL.   At that time,   development  of reparixin for use in pancreatic islet transplantation was supported [&lt;ulink linkID="1233026" linkType="Reference"&gt;1233026&lt;/ulink&gt;]. In September 2013, results were presented at the IPITA 2013. Data demonstrated that, the drug had shown to promote graft function after transplantation and demonstrated significant improvement in blood glucose control when compared to pretransplant condition  [&lt;ulink linkID="1481241" linkType="Reference"&gt;1481241&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2005, Dompe began a multicenter, randomized, double-blind, placebo controlled phase II trial (referenced &lt;ulink linkID="7743" linkType="Protocol"&gt;NCT00248040&lt;/ulink&gt;), in kidney transplanted patients (n = 72), to determine the safety and efficacy of reparixin in the prevention of delayed graft function. The primary endpoint would be creatinine clearance in the immediate post-transplant period. By October 2006, patient recruitment in the trial was ongoing, with data closure expected in July 2007 [&lt;ulink linkID="763592" linkType="Reference"&gt;763592&lt;/ulink&gt;]. By October 2012, data had shown that reparixin significantly improved pancreatic islet transplantation efficiency and prevents the death of beta-cells after transplantation, which leads to long term graft survival [&lt;ulink linkID="1334127" linkType="Reference"&gt;1334127&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2005, a US phase II trial (&lt;ulink linkID="7746" linkType="Protocol"&gt;NCT00224406&lt;/ulink&gt;) for ischemia-reperfusion injury after lung transplantation was initiated. The multicenter, randomized, double-blind study was to measure PaO2/inspired O2 fraction ratio on ICU admission and also at 24 h after ICU admission as the primary endpoints. The secondary endpoints were to be the PGD score, time of mechanical ventilation, duration of ICU stay, ICU mortality, acute rejection episodes, survival rate and pk profile. The study was to enroll 100 patients with last follow-up and data entry closure scheduled for May 2007 and August 2007, respectively [&lt;ulink linkID="652939" linkType="Reference"&gt;652939&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2010, a phase I clinical trial was planned in type I diabetes patients (n = 10) who have recieved a pancreatic islet transplantation as treatment [&lt;ulink linkID="1106783" linkType="Reference"&gt;1106783&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By January 2003, phase I trials of reparixin, administered by slow continuous iv infusion, were underway [&lt;ulink linkID="478756" linkType="reference"&gt;478756&lt;/ulink&gt;]. In August 2003, clinical data on reparixin, presented at Inflammation 2003 in Vancouver, Canada, revealed that the compound was safe and well tolerated in healthy volunteers and showed a favorable pharmacokinetic profile in two phase I trials [&lt;ulink linkID="500718" linkType="reference"&gt;500718&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Cancer&lt;/subtitle&gt;In April 2016, clinical data were presented at the 107th AACR Annual Meeting in New Orleans, LA, USA. The most common adverse event reported was fatigue. Reparixin was rapidly absorbed and metabolized; the Tmax and t1/2 were found to be 1 and 1.5 h, respectively [&lt;ulink linkID="1754840" linkType="Reference"&gt;1754840&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2015, a randomized, parallel assignment, double blind, phase II study (&lt;ulink linkID="222702" linkType="Protocol"&gt;NCT02370238&lt;/ulink&gt;; REP0114, 2014-004796-23; FRIDA) was planned to be initiated in April 2015, to assess &lt;ulink linkID="3803" linkType="Drug"&gt;paclitaxel&lt;/ulink&gt; alone or in combination with the drug  in patients (expected n  = 190) with metastatic breast cancer in the US, Czech Republic, Poland, Belgium, France, Spain and Italy. At that time, the study was expected to complete in February 2018 [&lt;ulink linkID="1638656" linkType="Reference"&gt;1638656&lt;/ulink&gt;]. In June 2015, the trial commenced [&lt;ulink linkID="1638656" linkType="Reference"&gt;1638656&lt;/ulink&gt;]. In April 2018, recruitment was ongoing and completion was expected in February 2019 [&lt;ulink linkID="1638656" linkType="Reference"&gt;1638656&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2011, reparixin was in phase II for cancer [&lt;ulink linkID="1266091" linkType="Reference"&gt;1266091&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2011, a phase Ib study (UMCC 2011.079) of reparixin and paclitaxel was initiated in patients in HER2-negative breast cancer [&lt;ulink linkID="1266093" linkType="Reference"&gt;1266093&lt;/ulink&gt;]. In December 2013, it was reported  at the 36th Annual CTRC-AACR San Antonio Breast Cancer Symposium, in San Antonio, TX that at that time, three patients had been recruited. The study was expected to enrol 40 patients [&lt;ulink linkID="1513013" linkType="Reference"&gt;1513013&lt;/ulink&gt;]. In December 2014, clinical data were presented at the 37th Annual San Antonio Breast Cancer Symposium in San Antonio, TX.  At 400 and 1200 mg dose level, reparixin treatment showed overall response rate (ORR) of 33 and 30%, respectively and showed progression free survival (PFS) of 33 and 20%, respectively at 6 months, while 800 mg reparixin showed both ORR and PFS of 0%. The recommended phase II dose was found to be 1200 mg tid [&lt;ulink linkID="1616574" linkType="Reference"&gt;1616574&lt;/ulink&gt;]&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In December 2016, preclinical data were presented at the 28th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics in Munich, Germany. In male Wistar rats, treatment with reparixin (8 mg/h/kg) showed a significant reduction of cold and mechanical allodynia induced by both chemotherapeutic agents, paclitaxel and oxaliplatin. Reparixin significantly protected against oxaliplatin-induced intraepidermal nerve fiber loss [&lt;ulink linkID="1878145" linkType="Reference"&gt;1878145&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2010, preclinical data were presented at the 28th Camerino-Cyprus-Noordwijkerhout Symposium in Camerino, Italy. In the streptozotozin-induced diabetes model, reparixin protected beta cell damage, improved engraftment, delayed graft rejection and prevented intrahepatic inflammatory and immune cell infiltration. Reparixin was also  tested against cancer stem cells; however, blockade of CXCR1 with reparixin led to cell death of CXCR1 positive cells [&lt;ulink linkID="1106783" linkType="Reference"&gt;1106783&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2004, preclinical data on reparixin were presented at the 34th SFN meeting in San Diego, CA. When administered at a dose of 15 mg/kg/day for 7 days following traumatic spinal cord injury, the compound promoted hindlimb function recovery. This recovery was associated with reduced post-injury cavity inflammatory cell invasion, IL-8 and TNF-alpha. Regeneration in the injured cord was observed [&lt;ulink linkID="566113" linkType="Reference"&gt;566113&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2003, preclinical data on reparixin were presented at Inflammation 2003, in Vancouver, Canada. In rat models of liver ischemia and delayed graft function of transplanted kidney, reparixin reduced polymorphonuclear cell (PMN) recruitment and tissue damage by up to 90%. It was found that reparixin does not inhibit IL-8 binding to nuclear receptors, whereas it does affect IL-8 receptor-induced signal transduction in human PMN [&lt;ulink linkID="500718" linkType="reference"&gt;500718&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In January 2003, preclinical data on reparixin were presented at the Chemokines and Chemokine Receptors Keystone symposium in Breckenridge, CO. In transient myocardial ischemia (30 mins) followed by reperfusion, reparixin reduced polymorphonuclear cell (PMN) infiltration by about 77% and reduced tissue damage by 39%. In a rat model of delayed graft function of transplanted kidney, reparixin inhibited PMN infiltration (100% interstitial and 50% intra-glomerular). Similar results were obtained in a liver ischemia model. Preliminary results suggested that reparixin was well tolerated with a favorable pharmacokinetic profile [&lt;ulink linkID="478756" linkType="reference"&gt;478756&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Inhibitors of IL-8 are found to cause potent and selective inhibition of IL-8 induced activation of leukocytes. By September 2000, the company had shown  that, when administered in vivo in an animal model of myocardial reperfusion injury in the rat, these IL-8 inhibitors reduced PMN recruitment and tissue damage by a molecular mechanism involving G proteins [&lt;ulink linkID="381532" linkType="reference"&gt;381532&lt;/ulink&gt;]. The lead compound, reparixin, showed potent inhibitory effects on IL-8 activity in vitro. The compound was also reported to be selective due to its inability to inhibit significantly PMN chemotaxis provoked by agents other than IL-8, eg, C5a and FMLP [&lt;ulink linkID="381652" linkType="reference"&gt;381652&lt;/ulink&gt;], [&lt;ulink linkID="418393" linkType="reference"&gt;418393&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In March 2015, the EMA's Pediatric Committee adopted a positive opinion on a product-specific waiver recommending the obligation to submit data from trials in children be waived for the prevention of graft rejection [&lt;ulink linkID="1646138" linkType="Reference"&gt;1646138&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="26028">Dompe Group</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3481">Islet cell transplant rejection</Indication><StatusDate>2012-10-23T00:00:00.000Z</StatusDate><Source id="1334127" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26028">Dompe Group</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3481">Islet cell transplant rejection</Indication><StatusDate>2012-10-23T00:00:00.000Z</StatusDate><Source id="1334127" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1071572">SatRx Llc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2988">Liver transplant rejection</Indication><StatusDate>2015-01-05T00:00:00.000Z</StatusDate><Source id="1623813" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26028">Dompe Group</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2015-06-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26028">Dompe Group</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2015-06-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26028">Dompe Group</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2018-07-17T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26028">Dompe Group</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3141">Lung transplant rejection</Indication><StatusDate>2018-07-17T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26028">Dompe Group</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2989">Kidney transplant rejection</Indication><StatusDate>2018-07-17T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26028">Dompe Group</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2989">Kidney transplant rejection</Indication><StatusDate>2018-07-17T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26028">Dompe Group</Company><Country id="IT">Italy</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2018-07-17T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="26028">Dompe Group</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3481">Islet cell transplant rejection</Indication><StatusDate>2012-09-25T00:00:00.000Z</StatusDate><Source id="1326926" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26028">Dompe Group</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3481">Islet cell transplant rejection</Indication><StatusDate>2010-10-07T00:00:00.000Z</StatusDate><Source id="1140863" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1071572">SatRx Llc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="2988">Liver transplant rejection</Indication><StatusDate>2012-10-25T00:00:00.000Z</StatusDate><Source id="1444232" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26028">Dompe Group</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3141">Lung transplant rejection</Indication><StatusDate>2005-05-01T00:00:00.000Z</StatusDate><Source id="652939" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26028">Dompe Group</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2989">Kidney transplant rejection</Indication><StatusDate>2005-10-31T00:00:00.000Z</StatusDate><Source id="763592" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26028">Dompe Group</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2989">Kidney transplant rejection</Indication><StatusDate>2005-10-31T00:00:00.000Z</StatusDate><Source id="763592" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26028">Dompe Group</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2011-12-31T00:00:00.000Z</StatusDate><Source id="1266093" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26028">Dompe Group</Company><Country id="IT">Italy</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2011-03-31T00:00:00.000Z</StatusDate><Source id="1266091" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26028">Dompe Group</Company><Country id="IT">Italy</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="515">Transplant rejection</Indication><StatusDate>2003-01-12T00:00:00.000Z</StatusDate><Source id="478756" type="CONFERENCE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26028">Dompe Group</Company><Country id="IT">Italy</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="515">Transplant rejection</Indication><StatusDate>2003-08-31T00:00:00.000Z</StatusDate><Source id="500718" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26028">Dompe Group</Company><Country id="IT">Italy</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1024">Reperfusion injury</Indication><StatusDate>2003-01-31T00:00:00.000Z</StatusDate><Source id="498560" type="CONFERENCE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="26028">Dompe Group</OwnerCompany><Country id="EU">EU</Country><Indication id="3481">Islet cell transplant rejection</Indication><AwardedIndication>Prevention of graft loss in pancreatic islet transplantation</AwardedIndication><DesignationType id="2">Prevention</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate>2015-03-31T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="26028">Dompe Group</OwnerCompany><Country id="US">US</Country><Indication id="3481">Islet cell transplant rejection</Indication><AwardedIndication>Prevention of graft loss in pancreatic islet transplantation</AwardedIndication><DesignationType id="2">Prevention</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2012-09-25T00:00:00.000Z</MileStoneDate><Source id="1326926" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="26028">Dompe Group</OwnerCompany><Country id="EU">EU</Country><Indication id="3481">Islet cell transplant rejection</Indication><AwardedIndication>Prevention of graft loss in pancreatic islet transplantation</AwardedIndication><DesignationType id="2">Prevention</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2011-09-27T00:00:00.000Z</MileStoneDate><Source id="1230604" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="26028">Dompe Group</OwnerCompany><Country id="EU">EU</Country><Indication id="3481">Islet cell transplant rejection</Indication><AwardedIndication>Prevention of graft loss in pancreatic islet transplantation</AwardedIndication><DesignationType id="2">Prevention</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2011-07-08T00:00:00.000Z</MileStoneDate><Source id="1208834" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="26028">Dompe Group</OwnerCompany><Country id="US">US</Country><Indication id="515">Transplant rejection</Indication><AwardedIndication>Prevention of delayed graft function in solid organ transplant</AwardedIndication><DesignationType id="2">Prevention</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2003-01-27T00:00:00.000Z</MileStoneDate><Source id="1623813" type="CORPORATE"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00516"><Name>CXCR1 chemokine</Name><SwissprotNumbers><Swissprot>P25024</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00517"><Name>CXCR2 chemokine</Name><SwissprotNumbers><Swissprot>P25025</Swissprot><Swissprot>P35343</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00989"><Name>IL-8 receptor</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1050615">ChemRar High Tech Center</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="26028">Dompe Group</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>C[C@H](c1ccc(cc1)CC(C)C)C(=O)NS(=O)(=O)C</Smiles></StructureSmiles><Deals><Deal id="145603" title="SatRx to collaborate with Dompe for the clinical development of Reparixin against early allograft dysfunction in liver transplanted patients in Russia"/></Deals><PatentFamilies><PatentFamily id="1269047" number="WO-2011042465" title="Sulfonamides for the prevention of diabetes"/><PatentFamily id="1343164" number="WO-2011042466" title="Inhibitors of CXCR1/2 as adjuvants in the transplant of pancreatic islets"/><PatentFamily id="2323732" number="WO-02062330" title="Use of (R)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs"/><PatentFamily id="2664321" number="WO-2014006115" title="Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction"/><PatentFamily id="3428880" number="US-20160311911" title="Methods for treating allergic airway inflammation"/><PatentFamily id="3508079" number="WO-2017007403" title="Methods and compounds for the alleviation and/or prevention of pain"/><PatentFamily id="3511049" number="WO-2017009323" title="IL-8 inhibitors for use in the treatment of certain urological disorders"/><PatentFamily id="3684159" number="US-20170165363" title="Cancer cell migration inhibitors and their use in therapeutic treatments"/><PatentFamily id="3725877" number="WO-2017121838" title="IL-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy"/><PatentFamily id="4013086" number="WO-2018067548" title="Prevention and treatment of diabetic nephropathy"/><PatentFamily id="4021950" number="WO-2018071687" title="Methods of treating pruritis"/><PatentFamily id="594117" number="US-20070208074" title="Methods and compositions for treating and preventing tumors"/><PatentFamily id="623852" number="WO-2005092315" title="Use of N-(2-aryl-propionyl)-sulfonamides for the treatment of spinal cord injury"/><PatentFamily id="911951" number="WO-00024710" title="N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them"/><PatentFamily id="923127" number="WO-2008039876" title="Cytokine signaling"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>12</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck KGaA" id="18101"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of California" id="20547"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Case Western Reserve University" id="20553"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Harvard University" id="20584"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johns Hopkins University" id="20596"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Karolinska Institutet" id="21110"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Boston Children's Hospital" id="24334"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dompe Group" id="26028"/><CountAsOwner>8</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>8</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>